Abstract
The clinical association between Coxsackievirus B (CVB) and methicillin-sensitive Staphylococcus aureus (MSSA) has not been well established in the current literature. Here, we report a case of a 29-year-old male who presented with fever and malaise 24 hours after noticing a pruritic lesion on the anterior foreleg that resembled a mosquito bite. After multiple ED visits, laboratory studies, and imaging tests, the patient was admitted for treatment of high fevers and pancytopenia. The final diagnosis was viral sepsis complicated by co-infection with MSSA.
Keywords: international travel, hypotension, pancytopenia, edema, lymphangitis, cellulitis, mssa, sepsis, vector borne disease, coxsackie b virus
Introduction
Coxsackievirus B (CVB) is a positive-sense, non-enveloped, single-strand RNA enterovirus of the Picornaviridae family that includes six different serotypes (B1-6) which are responsible for numerous clinical presentations [1-3]. Most enteroviruses, including CVB, are transmitted via the fecal-oral route [4,5]. Common symptoms include sore throat, fever, gastrointestinal distress, angina, and extreme lethargy [6]. The incubation period is two to six days, typically progressing as a self-limiting disease within 10 days for healthy adults. However, some cases have been reported to last more than six months [7]. Symptom severity depends on the immune status and age of the individual affected, with nearly all severe or lethal cases occurring in neonates or the immunocompromised [2]. CVB is not associated with any specific racial, gender, or ethnic group [6]. CVB infections frequently occur during the summer months [2,5,6]; however, in tropical regions, CVB seems to propagate year-round [8].
Methicillin-sensitive Staphylococcus aureus (MSSA) is a clinically pertinent gram-positive cocci [9], which is frequently seen in both the clinical and community environment [10]. Because MSSA is a normal flora of the nares, skin, and gastrointestinal infection, it does not usually cause symptomatic infection [11-13]. When it does, MSSA infection can present with various manifestations ranging from minor skin infections to endocarditis and sepsis [10,14]. One meta-analysis cited the mortality rate of MSSA bacteremia as 23.2% [15].
Co-infection of CVB and Staphylococcus aureus (MSSA and MRSA) is rarely reported in the literature, and in the cases available, presentation varied widely [16,17]. Here, we report a case of co-infection of CVB and MSSA cellulitis causing sepsis.
This article was previously presented in the poster competition at the 2023 American Medical Association - Medical Student Section Physicians of the Future Summit on January 28, 2023.
Case presentation
A 29-year-old male was traveling in the state of Virginia when he first noticed a 1-2 cm reddened pruritic lesion on the anterior foreleg, resembling a mosquito/spider bite (Figure 1). By the evening of day 1, the patient developed a temperature of 99.8F and malaise, which prompted a telehealth visit to his primary care provider. The patient was reassured that his condition was most likely self-limiting but advised to go to the ED if symptoms worsened.
Within two days of symptom onset, the lesion border has advanced to a 5-6 cm diameter and developed progressive ascending warmth, redness, and generalized limb discomfort (Figure 2). Continued changes in lesion appearance, malaise, and fever warranted an ED evaluation by the end of day 2. The patient had worsening lymphangitis/cellulitis but was afebrile and normotensive. A scant amount of lesion exudate was expressed and cultured. Because of suspicion of staphylococcal skin infection, trimethoprim/sulfamethoxazole (800/160) BID was prescribed for 10 days while awaiting culture results.
Five days later, the patient traveled eight hours by car and developed 2+ pitting edema, mild serosanguineous wound drainage, and increased pain but remained afebrile (Figure 3).
The patient applied compression stockings and elevated his legs. Within six hours, the patient developed a fever of 103.9 F, chills, and severe malaise. The patient self-administered acetaminophen 1000 mg every six hours (q6h), which decreased his temperature by about 1 degree when in full effect. Despite visible lesion improvement, the patient continued to experience moderate retro-orbital headache, difficulty with focusing/cognition, and severe lethargy (Figure 4). Two days later, the patient returned to the ED with the following vital signs: temperature 102.2F, heart rate 100, blood pressure 131/69, oxygen saturation 97% on room air, and respiratory rate 15 but was soon discharged after being switched to doxycycline 100 mg BID due to suspicion of inadequate antibiotic coverage (Table 1).
Table 1. Vital signs taken at the ED visit on day 9.
July 17, 0933 | |
Temperature (oral) | 38.9 C |
Heart rate | 100 |
Respiratory rate | 15 |
Blood pressure (systolic) | 131 |
Blood pressure (diastolic) | 69 |
Oxygen saturation | 97% |
Less than 24 hours later (day 10), the patient was admitted for antibiotic failure with weakness, blood pressure lability, lymphocytopenia, and witnessed syncope in the ED. Bedside arterial blood gases were notable for PaO2 of 28 mmHg, with all other standard values within normal ranges. CBC revealed a total WBC 5.86 x10-3/uL, platelets 142,000 per microliter (mcL), neutrophils 80.5%, lymphocytes 9.2%, and 7.8% eosinophils (Table 2). Vancomycin 2500 mg was started, followed by 1750 mg q12h infusion. On day 11, new, flat, red-purple, painless, subcutaneous lesions developed, and ceftaroline 600 mg q12h was added (Figure 5). Vital signs showed persistent hypotension and fever, and laboratory studies showed continued pancytopenia, hypocalcemia, and mild anemia. On day 11, the patient described a new sensation of extreme heat in both hands, perioral tingling, and anxiety (Tables 3-4). Infectious disease consultation was sought, and during the patient interview, a history of travel to the Dominican Republic four weeks prior was elicited. This prompted the collection of tick-borne/arbovirus panels due to concerns about tropical vectors, which had previously been deemed unlikely.
Table 2. Selected inpatient daily labs.
Jul 20, 1547 | Jul 21, 1418 | ||||||
BMP | CBC | CMP | CBC | ||||
eGFR | >60.0 mL/min/1.73 m2 | White blood cells | 2.93x10-3/uL | eGFR | >60.0 mL/min/1.73 m2 | White blood cells | 2.76x10-3/uL |
BUN/creatinine ratio | 10 mg/dL | Red blood cells | 4.15x10-6/uL | BUN/creatinine ratio | 10 mg/dL | Red blood cells | 4.27x10-6/uL |
Osmolality calc | 270 mosm/kg | Hemoglobin | 12.5 g/dL | Osmolality calc | 281 mosm/kg | Hemoglobin | 13.2 g/dL |
Sodium | 135 mEq/L | Hematocrit | 35.4% | Sodium | 139 mEq/L | Hematocrit | 36.6% |
Potassium | 4.1 mEq/L | MCV | 85.3 fL | Potassium | 3.9 mEq/L | MCV | 85.7 fL |
Chloride | 103 mEq/L | MCH | 30.1 pg | Chloride | 105 mEq/L | MCH | 30.9 pg |
Carbon dioxide | 22.0 mEq/L | MCHC | 35.3 g/dL | Carbon dioxide | 23.0 mEq/L | MCHC | 36.3 g/dL |
BUN | 11 mg/dL | RDW | 12.5% | BUN | 10 mg/dL | RDW | 12.4% |
Creatinine, serum | 1.1 mg/dL | Platelets | 106x10-3/uL | Creatinine, serum | 0.9 mg/dL | Platelets | 111x10-3/uL |
Glucose | 106 mg/dL | MPV | 10.5 fL | Glucose | 169 mg/dL | MPV | 10.2 fL |
Calcium | 8.1 mg/dL | Neutrophils | 44.5% | Calcium | 8.5 mg/dL | Neutrophils | 43.7% |
Anion gap | 10 mEq/L | Lymphocytes | 38.9% | Anion gap | 11 mEq/L | Lymphocytes | 42.9% |
Iron, serum | 42 mcg/dL | Monocytes | 8.2% | Albumin | 3.9 gm/dL | Monocytes | 6.3% |
Iron binding capacity | 211 mcg/dL | Eosinophils | 7.8% | Bilirubin, total | 0.3 mg/dL | Eosinophils | 7.1% |
Iron saturation | 20% | Basophils | 0.3% | AST (SGOT) | 21 U/L | Basophils | 0% |
Neutrophils, Abs | 1.3x10-3/μL | ALT (SGPT) | 20 IU/L | Neutrophils. Abs | 1.21x10-3/μL | ||
Lymphocytes, Abs | 1.14x10-3/μL | Alkaline phos | 53 IU/L | Lymphocytes, Abs | 1.18x10-3/μL | ||
Monocytes, Abs | 0.24x10-3/μL | Protein, total | 6.6 g/dL | Monocytes, Abs | 0.17x10-3/μL | ||
Eosinophils, Abs | 0.23x10-3/uL | Eosinophils, Abs | 0.20x10-3/uL | ||||
Basophils, Abs | 0.01x10-3/μL | Basophils, Abs | 0.01x10-3/μL |
Table 3. ED and inpatient vital signs from day 10.
Jul 19, 0118 | Jul 19, 0252 | Jul 19, 0933 | Jul 19, 1329 | Jul 19, 2354 | |
Temperature (oral) | 99.3 F | 101.8 F | 100.4 F | 102.6 F | 103.1 F |
Heart rate | 82 | 117 | 90 | 84 | 97 |
Oxygen saturation | 96% | 99% | 98% | 98% | 95% |
Blood pressure (systolic) | 145 | 86 | 104 | 113 | 97 |
Blood pressure (diastolic) | 81 | 56 | 62 | 58 | 53 |
Respiratory rate | 14 | 16 | 11 | 19 | 20 |
Table 4. ED and inpatient vital signs from days 11 and 12.
Jul 20, 0821 | Jul 20, 1149 | Jul 20, 1933 | Jul 21, 0321 | Jul 21, 0728 | Jul 21, 1322 | |
Temperature (oral) | 100.0 F | 98.6 F | 101.3 F | 102.2 F | 98.8 F | 98.3 F |
Heart rate | 81 | 67 | 88 | 92 | 78 | 68 |
Oxygen saturation | 94% | 97% | 98% | 96% | 98% | 98% |
Blood pressure (systolic) | 115 | 134 | 108 | 103 | 115 | 130 |
Blood pressure (diastolic) | 58 | 75 | 67 | 59 | 64 | 83 |
Respiratory rate | 18 | 16 | 17 | 18 | 15 | 14 |
Therapy continued as previously stated until day 13, when the patient became normotensive and afebrile overnight. He was discharged on day 13 and told to follow up in three weeks for blood work (Tables 5-6).
Table 5. Coxsackie B1-6 titers.
Coxsackie B1-6 antibodies | |||
Component | Value | Standard range | Flag |
Coxsackie B1 antibodies | <1:8 | <1:8 | |
Coxsackie B2 antibodies | <1:8 | <1:8 | |
Coxsackie B3 antibodies | 1:8 | <1:8 | H |
Coxsackie B4 antibodies | <1:8 | <1:8 | |
Coxsackie B5 antibodies | <1:8 | <1:8 | |
Coxsackie B6 antibodies | 1:8 | <1:8 | H |
Table 6. Three-week follow-up CMP and CBC.
Aug 19, 1440 | |||
CMP | CBC | ||
eGFR | >60.0 mL/min/1.73 m2 | White blood cells | 4.7x10-3/uL |
BUN/creatinine ratio | 9.80 mg/dL | Red blood cells | 4.93x10-6/uL |
Osmolality calc | 277.1 mosm/kg | Hemoglobin | 15.0 g/dL |
Sodium | 139 mEq/L | Hematocrit | 42.5% |
Potassium | 3.8 mEq/L | MCV | 86.1 fL |
Chloride | 105 mEq/L | MCH | 30.4 pg |
Carbon dioxide | 26.0 mEq/L | MCHC | 35.3 g/dL |
BUN | 10 mg/dL | RDW | 13.6% |
Creatinine, serum | 1.02 mg/dL | Platelets | 177x10-3/uL |
Glucose | 107 mg/dL | MPV | 8.2 fL |
Calcium | 9.5 mg/dL | Neutrophils | 57.8% |
Anion gap | 8 mEq/L | Lymphocytes | 33.7% |
Albumin | 4.5 gm/dL | Monocytes | 5.4% |
Bilirubin, total | 0.4 mg/dL | Eosinophils | 2.5% |
AST (SGOT) | 21 U/L | Basophils | 0.6% |
ALT (SGPT) | 30 IU/L | Neutrophils, Abs | 2.7x10-3/μL |
Alkaline phos | 54 IU/L | Lymphocytes, Abs | 1.6x10-3/μL |
Protein, total | 7.0 gm/dL | Monocytes, Abs | 0.3x10-3/μL |
Globulin, total | 2.5 g/dL | Eosinophils, Abs | 0.1x10-3/uL |
A/G ratio | 1.8 | Basophils, Abs | 0.0x10-3/μL |
Discussion
This patient was eventually diagnosed with viral sepsis secondary to CVB, complicated by co-infection with MSSA. Clinical identification and management of MSSA and CVB co-infection can prove challenging because both of these pathogens can present with a wide range of symptoms and severity [1-3,10,14]. In this patient, titers were significant for Coxsackie B3 and B6, which both have been shown to cause myopericarditis, aseptic meningitis, herpangina, and many other sequelae [18-20]. Additionally, MSSA can lead to various manifestations, ranging from minor skin infections to endocarditis and sepsis [10,14]. The patient’s clinical status appeared stable and mild for the initial five days before applying compression stockings, which immediately preceded a change in vital signs. The rapid change in temperature and new symptom onset suggest that rapidly mobilizing pooled lymphatic fluid accelerated the course of his infection.
Due to the atypical presentation and the broad nature of known infectious agents, a broad list of differential diagnoses was considered. Those included were multiple arboviruses, rocky mountain spotted fever, toxic shock syndrome (TSS), brown-recluse bite, enteric parasite, viral sepsis, and fever of unknown origin (FUO). This patient was traveling in Virginia when the lesion first appeared; however, the accelerated timeline of symptoms, obvious eschar, and lack of advancing border made rocky mountain spotted fever unlikely [21]. Since the initial wound culture was positive for MSSA, sepsis criteria were met on day 10, and subsequent negative cultures were collected after the initial seven days of TMP/SMX. Staphylococcal TSS was considered [22]. Without the development of worsening abscess/necrosis or multi-organ failure, TSS also was deemed unlikely [23]. Lymphangitis with a necrotic center is consistent with a spider bite, but significant edema and well-healed appearance by day 9 suggested other causes [24]. Travel history merited concern for parasites and arboviruses but was ruled out due to a lack of eosinophilia. While no direct causative agent was found, the resolution of symptoms by day 13 failed to meet the criteria for FUO [25].
At the patient’s three-week follow-up, labs returned significant for CVB antibodies. The final determination was viral sepsis complicated by co-infection with MSSA. After an exhaustive literature review, very few case reports could be found that describe a Staphylococcus aureus (MRSA and MSSA) co-infection with CVB. Published reports describe inconsistent and widely variable clinical sequelae that include myocarditis, eczema herpeticum, and sepsis [16,17].
Conclusions
While both pathogens are common, this case represents how co-infection can lead to various potentially life-threatening presentations. With minimal literature on the subject, we hope to spread awareness and encourage others to present similar cases regarding co-infections of MSSA and CVB.
The authors have declared that no competing interests exist.
Human Ethics
Consent was obtained or waived by all participants in this study
References
- 1.Seroprevalence of group B Coxsackieviruses: retrospective study in an Italian population. Sciandra I, Falasca F, Maida P, et al. J Med Virol. 2020 doi: 10.1002/jmv.26096. [DOI] [PubMed] [Google Scholar]
- 2.Enterovirus surveillance--United States, 1970-2005. Khetsuriani N, Lamonte-Fowlkes A, Oberst S, Pallansch MA. https://pubmed.ncbi.nlm.nih.gov/16971890/ MMWR Surveill Summ. 2006;55:1–20. [PubMed] [Google Scholar]
- 3.Ratification vote on taxonomic proposals to the International Committee on Taxonomy of Viruses (2016) Adams MJ, Lefkowitz EJ, King AM, et al. Arch Virol. 2016;161:2921–2949. doi: 10.1007/s00705-016-2977-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Group B coxsackievirus virulence. Tracy S, Gauntt C. Curr Top Microbiol Immunol. 2008;323:49–63. doi: 10.1007/978-3-540-75546-3_3. [DOI] [PubMed] [Google Scholar]
- 5.Coxsackievirus infection and associated diseases. Nekoua MP, Hober D. Microorganisms. 2022;10:1566. doi: 10.3390/microorganisms10081566. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Tariq N, Kyriakopoulos C. StatPearls [Internet] Treasure Island (FL): StatPearls Publishing; 2023. Group B Coxsackie virus. [Google Scholar]
- 7.Tissue tropism, pathology and pathogenesis of enterovirus infection. Muehlenbachs A, Bhatnagar J, Zaki SR. J Pathol. 2015;235:217–228. doi: 10.1002/path.4438. [DOI] [PubMed] [Google Scholar]
- 8.Coxsackieviruses (Picornaviridae) Pozzetto B, Gaudin OG. Encyclopedia of Virology. 1999:305–311. [Google Scholar]
- 9.The evolution of Staphylococcus aureus. Deurenberg RH, Stobberingh EE. Infect Genet Evol. 2008;8:747–763. doi: 10.1016/j.meegid.2008.07.007. [DOI] [PubMed] [Google Scholar]
- 10.Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG Jr. Clin Microbiol Rev. 2015;28:603–661. doi: 10.1128/CMR.00134-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Disseminated methicillin-susceptible Staphylococcus aureus infection. Perkins DR, Hall JA, Lopez LM, Cahuayme-Zuniga LJ. J Med Microbiol. 2018;67:83–86. doi: 10.1099/jmm.0.000644. [DOI] [PubMed] [Google Scholar]
- 12.Taylor TA, Unakal CG. StatPearls [Internet] Treasure Island (FL): StatPearls Publishing; 2023. Staphylococcus aureus infection. [Google Scholar]
- 13.Determinants of Staphylococcus aureus nasal carriage. Cole AM, Tahk S, Oren A, Yoshioka D, Kim YH, Park A, Ganz T. Clin Diagn Lab Immunol. 2001;8:1064–1069. doi: 10.1128/CDLI.8.6.1064-1069.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Cutaneous manifestations of Staphylococcus aureus disease. Howell ER, Phillips CM. Skinmed. 2007;6:274–279. doi: 10.1111/j.1540-9740.2007.06416.x. [DOI] [PubMed] [Google Scholar]
- 15.Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Clin Infect Dis. 2003;36:53–59. doi: 10.1086/345476. [DOI] [PubMed] [Google Scholar]
- 16.Coxsackie myocarditis with severe methicillin-resistant Staphylococcus aureus sepsis, multi-organ dysfunction syndrome, and posterior epidural spinal abscess: a case report. Morkar DN, Agarwal R, Patil RS. Indian J Crit Care Med. 2020;24:73–76. doi: 10.5005/jp-journals-10071-23333. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Eczema herpeticum in a patient with atopic dermatitis, Coxsackie B virus, and staphylococcal infection: a double skin damage. Pratico A, Fatuzzo V, Cucuzza M, La Mendola FC. Ind J Paediatr Derm. 2018;19:369–370. [Google Scholar]
- 18.Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever and other spotted fever group rickettsioses, ehrlichioses, and anaplasmosis - United States. Biggs HM, Behravesh CB, Bradley KK, et al. MMWR Recomm Rep. 2016;65:1–44. doi: 10.15585/mmwr.rr6502a1. [DOI] [PubMed] [Google Scholar]
- 19.Ross A, Shoff HW. StatPearls [Internet] Treasure Island (FL): StatPearls Publishing; 2023. Toxic shock syndrome. [PubMed] [Google Scholar]
- 20.Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Evans L, Rhodes A, Alhazzani W, et al. Intensive Care Med. 2021;47:1181–1247. doi: 10.1007/s00134-021-06506-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Anoka IA, Robb EL, Baker MB. StatPearls [Internet] Treasure Island (FL): StatPearls Publishing; 2023. Brown recluse spider toxicity. [PubMed] [Google Scholar]
- 22.Brown I, Finnigan NA. StatPearls [Internet] Treasure Island (FL): StatPearls Publishing; 2023. Fever of unknown origin. [Google Scholar]
- 23.Coxsackievirus B3 sequences in the myocardium of fatal cases in a cluster of acute myocarditis in Greece. Spanakis N, Manolis EN, Tsakris A, Tsiodras S, Panagiotopoulos T, Saroglou G, Legakis NJ. J Clin Pathol. 2005;58:357–360. doi: 10.1136/jcp.2004.020099. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Coxsackievirus B3 sequences in the blood of a neonate with congenital myocarditis, plus serological evidence of maternal infection. Bendig JW, Franklin OM, Hebden AK, Backhouse PJ, Clewley JP, Goldman AP, Piggott N. J Med Virol. 2003;70:606–609. doi: 10.1002/jmv.10437. [DOI] [PubMed] [Google Scholar]
- 25.Unusual cause of chest pain, Bornholm disease, a forgotten entity; case report and review of literature. Lal A, Akhtar J, Isaac S, Mishra AK, Khan MS, Noreldin M, Abraham GM. Respir Med Case Rep. 2018;25:270–273. doi: 10.1016/j.rmcr.2018.10.005. [DOI] [PMC free article] [PubMed] [Google Scholar]